Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha
Van Lieshout, A.W.T.; Creemers, M.C.W.; Radstake, T.R.D.J.; Elving, L.D.; van Riel, P.L.C.M.
Journal of Rheumatology 35(5): 938-939
2008
ISSN/ISBN: 0315-162X PMID: 18464319 Document Number: 618822
Document emailed within 1 workday
Related Documents
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571Feldmann, M.; Brennan, F.; Paleolog, E.; Taylor, P.; Maini, R.N. 1997: Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action European Cytokine Network 8(3): 297-300
Antoni, C.; Kalden, J.R. 1999: Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 17(6 Suppl 18: S73-S77
Pachot, A.; Arnaud, Béatrice.; Marrote, H.; Cazalis, M-Angélique.; Diasparra, J.; Gouraud, A.; Mougin, B.; Miossec, P. 2007: Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response Journal of Rheumatology 34(11): 2158-2161
Tsybul'ko, S.V.; Baranov, A.A.; Borodin, A.G.; Korshunov, N.I.; Kirdianov, S.Iu. 2001: Tumor necrosis factor-alpha and kidney damage in rheumatoid arthritis Terapevticheskii Arkhiv 73(5): 8-11
Dayer, J.-M. 2002: Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? Journal of Rheumatology. Suppl 65: 10-15
Garcia-Porrua, C.; Gonzalez-Gay, M.A.; Quevedo, V. 2006: Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? Journal of Rheumatology 33(2): 433; Author Reply 433-4
Tse, S.M.L.; Laxer, R.M.; Babyn, P.S.; Doria, A.S. 2006: Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept Journal of Rheumatology 33(6): 1186-1188
Fabris, M.; Di Poi, E.; D'Elia, A.; Damante, G.; Sinigaglia, L.; Ferraccioli, G. 2002: Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis Journal of Rheumatology 29(1): 29-33
Straub, R.H.; Härle, P.; Atzeni, F.; Weidler, C.; Cutolo, M.; Sarzi-Puttini, P. 2005: Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy Journal of Rheumatology 32(7): 1253-1258
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Dombrecht, E.J.; Aerts, N.E.; Schuerwegh, A.J.; Hagendorens, M.M.; Ebo, D.G.; Van Offel, J.F.; Bridts, C.H.; Stevens, W.J.; De Clerck, L.S. 2006: Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis Clinical and Experimental Rheumatology 24(1): 31-37
Sundrarjun, T.; Komindr, S.; Archararit, N.; Dahlan, W.; Puchaiwatananon, O.; Angthararak, S.; Udomsuppayakul, U.; Chuncharunee, S. 2004: Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis Journal of International Medical Research 32(5): 443-454
Belaiche, J.; Louis, E. 2000: Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies Revue Medicale de Liege 55(9): 827-832
den Broeder, A.A.; Creemers, M.C.W.; Fransen, J.; de Jong, E.; de Rooij, D-Jan.Ram.; Wymenga, A.; de Waal-Malefijt, M.; van den Hoogen, F.H.J. 2007: Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study Journal of Rheumatology 34(4): 689-695
Tanaka, N.; Kojima, K.; Muro, M.; Naomoto, Y.; Moreira, L.F.; Orita, K. 1995: Anti-proliferative and cytokinetic effects of tumor necrosis factor-alpha, interferon-alpha and 5-fluorouracil on a human tumor xenograft Anticancer Research 15(5b): 1949-1952
Kaneko, H.; Yamada, H.; Mizuno, S.; Udagawa, T.; Kazumi, Y.; Sekikawa, K.; Sugawara, I. 1999: Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice Laboratory Investigation; a Journal of Technical Methods and Pathology 79(4): 379-386
Maksymowych, W.P.; Inman, R.D.; Gladman, D.; Thomson, G.; Stone, M.; Karsh, J.; Russell, A.S. 2003: Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis Journal of Rheumatology 30(6): 1356-1363
Bendtzen, K.; Hansen, P.R.; Rieneck, K. 2004: Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor-alpha and interferon-gamma and has potential effect in the treatment of arthritis Ugeskrift for Laeger 166(37): 3203-3207
Alsalameh, S.; Mattka, B.; Al-Ward, R.; Lorenz, H.M.; Manger, B.; Pfizenmaier, K.; Grell, M.; Kalden, J.R. 1999: Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor Journal of Rheumatology 26(3): 645-653